What analyst predict for Abbott Laboratories NYSE:ABT ?
Abbott Laboratories NYSE:ABT
Abbott Laboratories is stock market daily expected to report earnings on 04/18/2018 before market open. The report will be for the fiscal Quarter ending Mar 2018. According to Investment Research, based on 11 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.58. The reported EPS for the same quarter last year was $0.48.
Overview of Abbott Laboratories NYSE:ABT
Abbott Laboratories is an American health care company with headquarters in Lake Bluff, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; it eventually grew to also sell research-based drugs, medical devices, diagnostics, and nutritional products. It split off the research-based pharmaceuticals into Abbvie in 2013. In 2015, revenues were $20.4 billion.
Abbott has a broad range of branded generic pharmaceuticals, medical devices, diagnostics, and nutrition products. The company’s in-vitro diagnostics business performs immunoassays and blood screening. Its medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other indicators of health. In 1985, the company developed the first HIV blood-screening test.
Abbott Point-of-Care manufactures diagnostic products for blood analysis to provide health care professionals diagnostics information at the point of patient care. Abbott also provides point-of-care cardiac assays to the emergency room.
|% Change from 52 Week Low|
|% Change from 52 Week High|